Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Empagliflozin in Early Diabetic Kidney Disease

NCT03173963 is registered in ClinicalTrials.gov with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) as lead sponsor.

NCT NCT03173963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03173963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Empagliflozin in Early Diabetic Kidney Disease
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase
Phase 3
Overall status
Withdrawn
Start date
May 27, 2017
Completion date
February 21, 2020
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus type 2, diabetic kidney disease